| TL | temporal lobe; terminal limen; thermolabile; thermoluminescence; threat to life; thymus-leukemia [an... |
|---|---|
| OCAA | Ovarian Cystadenocarcinoma Associated Antigen; Serous Mucinous Ovarian Tumor에만 나타남 |
| ATLA | adult T-cell leukemia virus-associated antigen; alternatives to laboratory animals |
| AuHAA | Australia hepatitis-associated antigen |
| CAPA | cancer-associated polypeptide antigen |
| I region associated antigens | Class II major histocompatibility (MHC) antigens. (18 Nov 1997) |
|---|---|
| islet neogenesis-associated protein | <chemical> Constituent of ilotropin; stimulates proliferation of pancreatic ductal cells in vitro; from hamsters and humans; amino acid sequence given in first source Synonym: ingap protein, ingap gene product (05 Dec 1998) |
| tat-associated kinase | <enzyme> Abbreviated tak; binds to activation domain of tat Registry number: EC 2.7.1.- Synonym: p-tefb, positive transcriptional elongation factor b (26 Jun 1999) |
| encephalomyelitis associated with carcinoma | An encephalomyelopathy as a remote effect of carcinoma, most often oat cell carcinoma of the lung; characterised by extensive nerve cell loss, which may be diffuse, but often predominates in particular portions of the central nervous system, particularly the limbic lobes, medulla, cerebellum, and gray matter of the spinal cord. Synonym: carcinomatous encephalomyelopathy, encephalomyelitis associated with carcinoma, paracarcinomatous encephalomyelopathy. (05 Mar 2000) |
| ergot alkaloid-associated heart disease | Heart disease caused by endomyocardial fibrosis which extends into valve structures, producing stenosis and/or regurgitation, associated with ergot alkaloid use. (05 Mar 2000) |
| Kaposi sarcoma associated herpesvirus protease | <enzyme> Genbank af010430 Registry number: EC 3.4.21.- Synonym: kshv protease, human herpesvirus 8 protease (26 Jun 1999) |
| lipoprotein-associated coagulation inhibitor | Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex. (05 Mar 2000) |
| lymphadenopathy-associated virus | <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified. Type 1: the retrovirus recognised as the agent that induces AIDS. Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa. Acronym: HIV (11 Nov 1997) |
| lymphoma, mucosa-associated lymphoid tissue | Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire malt tissue as a result of an immunologically mediated disorder. (12 Dec 1998) |
| lysosome associated membrane glycoprotein | <protein> Lysosome specific integral membrane glycoproteins. Long luminal domain, short transmembrane domain, very short cytoplasmic tail. Function not yet clear. (18 Nov 1997) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |